Bispecific antibodies, such as teclistamab, which binds to BCMA on myeloma cells and CD3 on T cells, provide an off-the-shelf treatment option, especially useful for patients who may not be candidates for CAR-T therapy due to manufacturing time or prior lymphodepletion requirements [21,22]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.